Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $47.25 Average Target Price from Brokerages

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have received an average recommendation of "Buy" from the fifteen brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, twelve have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $45.54.

Several analysts have commented on DYN shares. Chardan Capital reiterated a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a research note on Friday, May 9th. JPMorgan Chase & Co. cut their target price on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st. Piper Sandler cut their target price on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. BMO Capital Markets initiated coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They set an "outperform" rating and a $50.00 target price on the stock. Finally, Scotiabank initiated coverage on Dyne Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price target on the stock.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of DYN. abrdn plc bought a new stake in shares of Dyne Therapeutics in the fourth quarter worth about $608,000. Raymond James Financial Inc. bought a new stake in shares of Dyne Therapeutics in the fourth quarter worth about $2,340,000. Barclays PLC increased its holdings in shares of Dyne Therapeutics by 162.2% in the third quarter. Barclays PLC now owns 207,309 shares of the company's stock worth $7,446,000 after purchasing an additional 128,246 shares during the last quarter. Schroder Investment Management Group increased its holdings in shares of Dyne Therapeutics by 63.3% in the fourth quarter. Schroder Investment Management Group now owns 147,002 shares of the company's stock worth $3,477,000 after purchasing an additional 56,961 shares during the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of Dyne Therapeutics by 54.5% in the fourth quarter. Wells Fargo & Company MN now owns 38,754 shares of the company's stock worth $913,000 after purchasing an additional 13,677 shares during the last quarter. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics stock traded up $0.74 during midday trading on Thursday, hitting $12.70. The company had a trading volume of 2,219,105 shares, compared to its average volume of 1,632,272. The stock has a market capitalization of $1.44 billion, a P/E ratio of -3.57 and a beta of 1.19. The company has a 50 day moving average of $10.33 and a 200 day moving average of $16.00. Dyne Therapeutics has a 52-week low of $6.36 and a 52-week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.17). Equities research analysts forecast that Dyne Therapeutics will post -3.44 EPS for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.